Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • zydus

    Tag: zydus

    You Searched For "zydus"
    Zydus gets USFDA final approval for Imatinib Mesylate Tablets

    Zydus gets USFDA final approval for Imatinib Mesylate Tablets

    Medical Dialogues Bureau9 April 2020 7:31 AM GMT
    Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Imatinib Mesylate Tablets, 100 mg and 400 mg. (US RLD: Gleevec®...
    Zydus gets USFDA final approval for Perphenazine Tablets USP

    Zydus gets USFDA final approval for Perphenazine Tablets USP

    Medical Dialogues Bureau8 April 2020 7:26 AM GMT
    Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg. (US RLD: Trilafon®...
    Coronavirus: Zydus Wellness launches hand sanitizer under Nycil brand to meet growing demand

    Coronavirus: Zydus Wellness launches hand sanitizer under Nycil brand to meet growing demand

    Medical Dialogues Bureau2 April 2020 7:30 AM GMT
    Nycil sanitizer consists of neem and aloevera extracts that helps kill 99.9 percent germs, Zydus Wellness said
    Worlds first drug for treatment of Non-Cirrhotic NASH approved: Zydus

    World's first drug for treatment of Non-Cirrhotic NASH approved: Zydus

    Medical Dialogues Bureau6 March 2020 8:56 AM GMT
    Saroglitazar is uniquely poised with its dual PPAR alpha and gamma properties – reducing the comorbidities (dyslipidemia, hypertriglyceridemia,...
    Zydus gets DCGI nod for Phase I clinical trial of ZYBK2b to treat Rheumatoid Arthritis

    Zydus gets DCGI nod for Phase I clinical trial of ZYBK2b to treat Rheumatoid Arthritis

    Medical Dialogues Bureau4 March 2020 5:04 AM GMT
    ZYBK2 has been specifically designed to inhibit HLA-DRB1 Shared Epitope (SE) that determines the susceptibility of a person to develop rheumatoid...
    Zydus Cadila gets USFDA nod for Colesevelam Hydrochloride tablets for lowering cholesterol

    Zydus Cadila gets USFDA nod for Colesevelam Hydrochloride tablets for lowering cholesterol

    Medical Dialogues Bureau10 Oct 2019 6:04 AM GMT
    Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Colesevelam Hydrochloride tablets,...
    Zydus Cadila total income up by 21 percent to Rs 3496 crore in Q1

    Zydus Cadila total income up by 21 percent to Rs 3496 crore in Q1

    Medical Dialogues Bureau10 Aug 2019 7:13 AM GMT
    During the quarter, Zydus Cadila entered into a marketing alliance with SIFI, the Italian leader in the development of therapeutic solutions for...
    Cadila Healthcare gets OAI letter from USFDA for Moraiya facility

    Cadila Healthcare gets OAI letter from USFDA for Moraiya facility

    Medical Dialogues Bureau8 Aug 2019 4:30 AM GMT
    The company has received a letter from the USFDA classifying the inspection conducted at its Moraiya facility from April 22 to May 3 as OAI, Cadila...
    Zydus Cadila completes phase III trial of Diabetes drug Lipaglyn in India

    Zydus Cadila completes phase III trial of Diabetes drug Lipaglyn in India

    Medical Dialogues Bureau5 Aug 2019 4:30 AM GMT
    Saroglitazar Magnesium was launched in India during September 2013, under the brand name 'Lipaglyn', for the treatment of hypertriglyceridemia and...
    Zydus Cadila arm gets USFDA nod for generic version of Adderall XR capsules in US

    Zydus Cadila arm gets USFDA nod for generic version of Adderall XR capsules in US

    Medical Dialogues Bureau21 July 2019 4:30 AM GMT
    The product is a generic version of Adderall XR capsules and will be manufactured at Nesher Pharmaceuticals' manufacturing facility at St Louis in the...
    Patients with NASH have been enrolled in 3 phase III trials of Saroglitazar, says Zydus Cadila

    Patients with NASH have been enrolled in 3 phase III trials of Saroglitazar, says Zydus Cadila

    Medical Dialogues Bureau18 July 2019 3:47 AM GMT
    "Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico," Cadila Healthcare, the listed entity of the group,...
    Zydus Cadila gets USFDA nod for generic Misoprostol tablets to treat ulcers

    Zydus Cadila gets USFDA nod for generic Misoprostol tablets to treat ulcers

    Medical Dialogues Bureau5 July 2019 6:22 AM GMT
    New Delhi: Drug firm Zydus Cadila Wednesday said it has received the final nod from the US health regulator to market its generic Misoprostol tablets...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    X